| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.967 | 0.004 | 0.969 | Cyclophilin D inhibitor | 0.969 0.004 DBMET01517 0.967 0.004 DBMET01518 | DBMET01517 | |
| 0.947 | 0.001 | 0.966 | Insulin sensitizer | 0.966 0.001 DBMET01517 0.637 0.003 DBMET01518 | DBMET01517 | |
| 0.802 | 0.004 | 0.814 | Hypoglycemic | 0.814 0.004 DBMET01517 0.792 0.004 DBMET01518 | DBMET01517 | |
| 0.58 | 0.003 | 0.58 | Peroxisome proliferator-activated receptor gamma agonist | 0.575 0.003 DBMET01517 0.532 0.003 DBMET01518 | ||
| 0.565 | 0.008 | 0.577 | Hypolipemic | 0.577 0.008 DBMET01517 0.559 0.009 DBMET01518 | DBMET01517 | |
| 0.51 | 0 | 0.51 | Thiazolidinedione | 0.471 0 DBMET01517 0.453 0 DBMET01518 | ||
| 0.49 | 0.004 | 0.496 | Sodium/bile acid cotransporter inhibitor | 0.496 0.004 DBMET01517 0.453 0.007 DBMET01518 | DBMET01517 | |
| 0.42 | 0.058 | 0.438 | Antiobesity | 0.438 0.053 DBMET01517 0.366 0.08 DBMET01518 | DBMET01517 | |
| 0.327 | 0.032 | 0.327 | Cyclic AMP phosphodiesterase inhibitor | 0.319 0.035 DBMET01517 0.234 0.072 DBMET01518 | ||
| 0.251 | 0.005 | 0.282 | Aldose reductase inhibitor | 0.278 0.005 DBMET01517 0.282 0.005 DBMET01518 | DBMET01518 | |
| 0.217 | 0.008 | 0.224 | ABCA1 expression enhancer | 0.224 0.007 DBMET01517 0.17 0.013 DBMET01518 | DBMET01517 | |
| 0.275 | 0.067 | 0.275 | Cardiotonic | 0.255 0.079 DBMET01517 0.209 0.11 DBMET01518 | ||
| 0.245 | 0.054 | 0.285 | ErbB-1 antagonist | 0.233 0.061 DBMET01517 0.285 0.037 DBMET01518 | DBMET01518 | |
| 0.16 | 0.003 | 0.174 | Free fatty acid receptor 1 agonist | 0.154 0.003 DBMET01517 0.174 0.003 DBMET01518 | DBMET01518 | |
| 0.151 | 0.014 | 0.246 | Adrenaline agonist | 0.246 0.005 DBMET01517 0.151 0.014 DBMET01518 | DBMET01517 | |
| 0.157 | 0.024 | 0.2 | AMP-activated protein kinase stimulant | 0.2 0.011 DBMET01517 0.113 0.055 DBMET01518 | DBMET01517 | |
| 0.183 | 0.052 | 0.194 | Interleukin 6 antagonist | 0.194 0.044 DBMET01517 0.17 0.064 DBMET01518 | DBMET01517 | |
| 0.133 | 0.004 | 0.144 | Estrogen-related receptor alpha antagonist | 0.134 0.004 DBMET01517 0.144 0.004 DBMET01518 | DBMET01518 | |
| 0.17 | 0.056 | 0.296 | Insulin secretagoues | 0.184 0.045 DBMET01517 0.296 0.013 DBMET01518 | DBMET01518 | |
| 0.239 | 0.132 | 0.299 | Angiogenesis inhibitor | 0.205 0.164 DBMET01517 0.299 0.093 DBMET01518 | DBMET01518 | |
| 0.164 | 0.059 | 0.208 | Lipid peroxidase inhibitor | 0.208 0.038 DBMET01517 0.167 0.057 DBMET01518 | DBMET01517 | |
| 0.113 | 0.011 | 0.115 | Peroxisome proliferator-activated receptor gamma antagonist | 0.115 0.011 DBMET01517 0.085 0.028 DBMET01518 | DBMET01517 | |
| 0.161 | 0.063 | 0.216 | NOS3 expression enhancer | 0.216 0.035 DBMET01517 0.211 0.037 DBMET01518 | DBMET01517 | |
| 0.144 | 0.052 | 0.144 | Epidermal growth factor receptor kinase inhibitor | 0.127 0.065 DBMET01517 0.136 0.058 DBMET01518 | ||
| 0.193 | 0.11 | 0.205 | Vasodilator | 0.205 0.101 DBMET01517 | DBMET01517 | |
| 0.089 | 0.021 | 0.106 | Maillard reaction inhibitor | 0.106 0.014 DBMET01517 0.093 0.02 DBMET01518 | DBMET01517 | |
| 0.077 | 0.019 | 0.077 | Peroxisome proliferator-activated receptor alpha agonist | 0.072 0.021 DBMET01517 0.043 0.038 DBMET01518 | ||
| 0.085 | 0.032 | 0.085 | Phosphodiesterase III inhibitor | 0.073 0.041 DBMET01517 0.072 0.041 DBMET01518 | ||
| 0.096 | 0.048 | 0.096 | Epidermal growth factor antagonist | 0.084 0.06 DBMET01517 0.089 0.054 DBMET01518 | ||
| 0.074 | 0.027 | 0.113 | Phosphodiesterase 1B inhibitor | 0.058 0.045 DBMET01517 0.113 0.011 DBMET01518 | DBMET01518 | |
| 0.082 | 0.041 | 0.1 | Lipase inhibitor | 0.095 0.03 DBMET01517 0.1 0.027 DBMET01518 | DBMET01518 | |
| 0.049 | 0.01 | 0.052 | Peroxisome proliferator-activated receptor delta antagonist | 0.052 0.009 DBMET01517 0.037 0.018 DBMET01518 | DBMET01517 | |
| 0.05 | 0.017 | 0.078 | Beta adrenoreceptor agonist | 0.078 0.005 DBMET01517 0.054 0.012 DBMET01518 | DBMET01517 | |
| 0.054 | 0.022 | 0.054 | Phosphodiesterase 3B inhibitor | 0.054 0.022 DBMET01517 0.045 0.029 DBMET01518 | ||
| 0.103 | 0.072 | 0.103 | Alpha 2b adrenoreceptor antagonist | |||
| 0.157 | 0.127 | 0.157 | MAP kinase kinase 5 inhibitor | 0.157 0.126 DBMET01518 | ||
| 0.116 | 0.096 | 0.116 | Growth factor antagonist | 0.115 0.097 DBMET01518 | ||
| 0.065 | 0.058 | 0.085 | Telomerase inhibitor | 0.072 0.05 DBMET01517 0.085 0.042 DBMET01518 | DBMET01518 | |
| 0.028 | 0.021 | 0.03 | DNA polymerase III inhibitor | 0.027 0.023 DBMET01517 0.03 0.016 DBMET01518 | DBMET01518 | |
| 0.069 | 0.069 | 0.081 | TIE-2 antagonist | 0.081 0.056 DBMET01518 | DBMET01518 | |
| 0.072 | 0.073 | 0.098 | MAP kinase kinase 7 inhibitor | 0.098 0.014 DBMET01517 | DBMET01517 | |
| 0.045 | 0.047 | 0.048 | Sodium/calcium exchanger inhibitor | 0.048 0.039 DBMET01518 | DBMET01518 | |
| 0.102 | 0.104 | 0.16 | Bone formation stimulant | 0.129 0.077 DBMET01517 0.16 0.052 DBMET01518 | DBMET01518 | |
| 0.069 | 0.072 | 0.081 | TIE antagonist | 0.081 0.058 DBMET01518 | DBMET01518 | |
| 0.022 | 0.027 | 0.044 | Thyroid hormone agonist | 0.044 0.005 DBMET01517 0.041 0.006 DBMET01518 | DBMET01517 | |
| 0.019 | 0.025 | 0.03 | Beta 1 adrenoreceptor agonist | 0.03 0.008 DBMET01517 0.025 0.012 DBMET01518 | DBMET01517 | |
| 0.077 | 0.084 | 0.093 | Phosphodiesterase I inhibitor | 0.093 0.054 DBMET01518 | DBMET01518 | |
| 0.077 | 0.085 | 0.109 | Platelet activating factor alpha antagonist | 0.109 0.052 DBMET01518 | DBMET01518 | |
| 0.068 | 0.08 | 0.096 | ErbB-3 antagonist | 0.096 0.044 DBMET01518 | DBMET01518 | |
| 0.006 | 0.02 | 0.016 | Beta 3 adrenoreceptor agonist | 0.016 0.005 DBMET01517 0.012 0.008 DBMET01518 | DBMET01517 | |
| 0.055 | 0.078 | 0.069 | Beta 2 adrenoreceptor agonist | 0.069 0.02 DBMET01517 | DBMET01517 | |
| 0.142 | 0.175 | 0.201 | Antioxidant | 0.201 0.112 DBMET01517 | DBMET01517 | |
| 0.054 | 0.1 | 0.091 | Platelet growth factor antagonist | 0.091 0.047 DBMET01518 | DBMET01518 | |
| 0.109 | 0.156 | 0.119 | Death-associated protein kinase 1 inhibitor | 0.119 0.117 DBMET01518 | DBMET01518 | |
| 0.053 | 0.104 | 0.068 | Adenosine A3 receptor antagonist | 0.068 0.062 DBMET01518 | DBMET01518 | |
| 0.072 | 0.137 | 0.1 | RET inhibitor | 0.1 0.097 DBMET01518 | DBMET01518 | |
| 0.061 | 0.174 | 0.078 | Estrogen-related receptor beta agonist | 0.078 0.073 DBMET01517 | DBMET01517 | |
| 0.05 | 0.218 | 0.135 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.135 0.089 DBMET01518 | DBMET01518 | |
| 0.085 | 0.294 | 0.176 | Prostaglandin dehydrogenase inhibitor | 0.176 0.175 DBMET01518 | DBMET01518 | |
| 0.053 | 0.265 | 0.11 | Estrogen antagonist | 0.11 0.075 DBMET01517 | DBMET01517 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |